- Home
- HL vs IOVA Comparison
HL vs IOVA Comparison
Compare HL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- IOVA
- Stock Information
- Founded
- HL 1891
- IOVA 2007
- Country
- HL United States
- IOVA United States
- Employees
- HL N/A
- IOVA N/A
- Industry
- HL Precious Metals
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HL Basic Materials
- IOVA Health Care
- Exchange
- HL Nasdaq
- IOVA Nasdaq
- Market Cap
- HL 3.6B
- IOVA 3.0B
- IPO Year
- HL N/A
- IOVA N/A
- Fundamental
- Price
- HL $5.52
- IOVA $8.55
- Analyst Decision
- HL Strong Buy
- IOVA Strong Buy
- Analyst Count
- HL 3
- IOVA 9
- Target Price
- HL $7.92
- IOVA $23.33
- AVG Volume (30 Days)
- HL 13.4M
- IOVA 8.6M
- Earning Date
- HL 11-06-2024
- IOVA 11-07-2024
- Dividend Yield
- HL 0.72%
- IOVA N/A
- EPS Growth
- HL N/A
- IOVA N/A
- EPS
- HL N/A
- IOVA N/A
- Revenue
- HL $840,960,000.00
- IOVA $90,858,000.00
- Revenue This Year
- HL $31.02
- IOVA $13,827.67
- Revenue Next Year
- HL $5.55
- IOVA $183.70
- P/E Ratio
- HL N/A
- IOVA N/A
- Revenue Growth
- HL 11.48
- IOVA 12751.20
- 52 Week Low
- HL $3.33
- IOVA $5.41
- 52 Week High
- HL $7.68
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- HL 35.24
- IOVA 38.84
- Support Level
- HL $5.54
- IOVA $7.98
- Resistance Level
- HL $5.80
- IOVA $10.86
- Average True Range (ATR)
- HL 0.26
- IOVA 0.64
- MACD
- HL -0.02
- IOVA -0.26
- Stochastic Oscillator
- HL 15.00
- IOVA 12.58
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Nevada Operations. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada , United States and Mexico and it derives a majority of its revenue from United States.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.